Published in Crit Care on March 21, 2011
Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis (2013) 5.00
Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol (2013) 4.38
Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding. Physiol Rev (2013) 1.72
Biomarkers of sepsis. Crit Rev Clin Lab Sci (2013) 1.48
Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis. Crit Care (2014) 1.48
A prospective analysis of lymphocyte phenotype and function over the course of acute sepsis. Crit Care (2012) 1.41
Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis. Crit Care (2013) 1.37
The new normal: immunomodulatory agents against sepsis immune suppression. Trends Mol Med (2014) 1.30
BTLA expression contributes to septic morbidity and mortality by inducing innate inflammatory cell dysfunction. J Leukoc Biol (2012) 1.22
The changing immune system in sepsis: is individualized immuno-modulatory therapy the answer? Virulence (2013) 1.15
Trauma equals danger--damage control by the immune system. J Leukoc Biol (2012) 1.15
T cells from patients with Candida sepsis display a suppressive immunophenotype. Crit Care (2016) 1.10
Monitoring the immune response in sepsis: a rational approach to administration of immunoadjuvant therapies. Curr Opin Immunol (2013) 1.09
B and T lymphocyte attenuator expression on CD4+ T-cells associates with sepsis and subsequent infections in ICU patients. Crit Care (2013) 1.03
Clinical review: flow cytometry perspectives in the ICU - from diagnosis of infection to monitoring of injury-induced immune dysfunctions. Crit Care (2011) 0.97
Impact of sepsis on CD4 T cell immunity. J Leukoc Biol (2014) 0.94
Persistent inflammation and T cell exhaustion in severe sepsis in the elderly. Crit Care (2014) 0.90
Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease. Immunity (2016) 0.88
Monocyte programmed death ligand-1 expression after 3-4 days of sepsis is associated with risk stratification and mortality in septic patients: a prospective cohort study. Crit Care (2016) 0.88
Biomarkers for Sepsis: What Is and What Might Be? Biomark Insights (2015) 0.87
Farnesyltransferase inhibitor FTI-277 reduces mortality of septic mice along with improved bacterial clearance. J Pharmacol Exp Ther (2011) 0.87
BTLA as a biomarker and mediator of sepsis-induced immunosuppression. Crit Care (2013) 0.87
CD137 expressed on neutrophils plays dual roles in antibacterial responses against Gram-positive and Gram-negative bacterial infections. Infect Immun (2013) 0.85
Inflammatory mechanisms in sepsis: elevated invariant natural killer T-cell numbers in mouse and their modulatory effect on macrophage function. Shock (2013) 0.85
Galectin-9 prolongs the survival of septic mice by expanding Tim-3-expressing natural killer T cells and PDCA-1+ CD11c+ macrophages. Crit Care (2013) 0.85
Active players in resolution of shock/sepsis induced indirect lung injury: immunomodulatory effects of Tregs and PD-1. J Leukoc Biol (2014) 0.83
Tuftsin-derived T-peptide prevents cellular immunosuppression and improves survival rate in septic mice. Sci Rep (2015) 0.82
To be, or not to be immunocompetent. Crit Care (2013) 0.82
Helminths and their implication in sepsis - a new branch of their immunomodulatory behaviour? Pathog Dis (2013) 0.81
Peroxisome proliferator-activated receptor γ co-activator 1-α as a critical co-activator of the murine hepatic oxidative stress response and mitochondrial biogenesis in Staphylococcus aureus sepsis. J Biol Chem (2013) 0.81
Role of circulating lymphocytes in patients with sepsis. Biomed Res Int (2014) 0.80
Persistent lymphopenia is a risk factor for ICU-acquired infections and for death in ICU patients with sustained hypotension at admission. Ann Intensive Care (2017) 0.80
Immunotherapy: A promising approach to reverse sepsis-induced immunosuppression. Pharmacol Res (2016) 0.79
Uncontrolled sepsis: a systematic review of translational immunology studies in intensive care medicine. Intensive Care Med Exp (2014) 0.79
Sepsis-induced potentiation of peritoneal macrophage migration is mitigated by programmed cell death receptor-1 gene deficiency. J Innate Immun (2013) 0.79
Decreased PD-1/PD-L1 Expression Is Associated with the Reduction in Mucosal Immunoglobulin A in Mice with Intestinal Ischemia Reperfusion. Dig Dis Sci (2015) 0.78
Sepsis in PD-1 light. Crit Care (2016) 0.78
FLT3 Ligand Treatment Attenuates T Cell Dysfunction and Improves Survival in A Murine Model of Burn Wound Sepsis. Shock (2016) 0.78
Is boosting the immune system in sepsis appropriate? Crit Care (2014) 0.77
A Novel Role for Programmed Cell Death Receptor Ligand-1 (PD-L1) in Sepsis-Induced Intestinal Dysfunction. Mol Med (2016) 0.77
Increased PD-1 Expression and Altered T Cell Repertoire Diversity Predict Mortality in Patients with Septic Shock: A Preliminary Study. PLoS One (2017) 0.76
The Expression of Programmed Death-1 on CD4+ and CD8+ T Lymphocytes in Patients with Type 2 Diabetes and Severe Sepsis. PLoS One (2016) 0.75
Balanced control of both hyper and hypo-inflammatory phases as a new treatment paradigm in sepsis. J Thorac Dis (2016) 0.75
Complement C5a induces PD-L1 expression and acts in synergy with LPS through Erk1/2 and JNK signaling pathways. Sci Rep (2016) 0.75
Soluble B and T Lymphocyte Attenuator Correlates to Disease Severity in Sepsis and High Levels Are Associated with an Increased Risk of Mortality. PLoS One (2017) 0.75
Soluble programmed cell death receptor-1 (sPD-1): a potential biomarker with anti-inflammatory properties in human and experimental acute respiratory distress syndrome (ARDS). J Transl Med (2016) 0.75
Efficacy of β-Lactam-plus-Macrolide Combination Therapy in a Mouse Model of Lethal Pneumococcal Pneumonia. Antimicrob Agents Chemother (2016) 0.75
Altered T Lymphocyte Proliferation upon Lipopolysaccharide Challenge Ex Vivo. PLoS One (2015) 0.75
Contribution of programmed cell death receptor (PD)-1 to Kupffer cell dysfunction in murine polymicrobial sepsis. Am J Physiol Gastrointest Liver Physiol (2016) 0.75
A grim picture, indeed. Crit Care Med (2013) 0.75
When host defense goes awry: Modeling sepsis-induced immunosuppression. Drug Discov Today Dis Models (2012) 0.75
Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis. Chin Med J (Engl) (2017) 0.75
Emerging infection and sepsis biomarkers: will they change current therapies? Expert Rev Anti Infect Ther (2016) 0.75
Evaluation of mRNA Biomarkers to Identify Risk of Hospital Acquired Infections in Children Admitted to Paediatric Intensive Care Unit. PLoS One (2016) 0.75
Functional characterization of T-cells from palatine tonsils in patients with chronic tonsillitis. PLoS One (2017) 0.75
Impaired polyfunctionality of CD8(+) T cells in severe sepsis patients with human cytomegalovirus reactivation. Exp Mol Med (2017) 0.75
Expression of C/EBPβ in myeloid progenitors during sepsis promotes immunosuppression. Mol Immunol (2017) 0.75
Monocyte programmed death ligand-1 expression is an early marker for predicting infectious complications in acute pancreatitis. Crit Care (2017) 0.75
Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med (2001) 46.58
The pathophysiology and treatment of sepsis. N Engl J Med (2003) 21.67
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature (2006) 20.00
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med (2000) 19.81
PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol (2008) 19.24
Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med (2006) 13.15
PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol (2001) 12.26
Sepsis in European intensive care units: results of the SOAP study. Crit Care Med (2006) 11.78
Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med (2007) 10.02
Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J (1992) 8.86
PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med (2006) 8.18
SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol (2004) 4.58
Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol (2001) 4.49
PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. Proc Natl Acad Sci U S A (2009) 4.23
Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction. J Virol (2007) 3.83
Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection. Nat Med (2010) 3.81
PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol (2002) 3.78
Immunotherapy for sepsis--a new approach against an ancient foe. N Engl J Med (2010) 3.62
Bench-to-bedside review: endotoxin tolerance as a model of leukocyte reprogramming in sepsis. Crit Care (2006) 3.19
Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization. Gastroenterology (2008) 2.95
PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors. Blood (2007) 2.93
Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony. Mol Med (2008) 2.93
Toward an epidemiology and natural history of SIRS (systemic inflammatory response syndrome) JAMA (1993) 2.88
Normal responses to injury prevent systemic inflammation and can be immunosuppressive. Am J Respir Crit Care Med (2001) 2.82
Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. J Leukoc Biol (2010) 2.81
Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med (2006) 2.56
Increased circulating regulatory T cells (CD4(+)CD25 (+)CD127 (-)) contribute to lymphocyte anergy in septic shock patients. Intensive Care Med (2008) 2.34
Cell-specific expression and pathway analyses reveal alterations in trauma-related human T cell and monocyte pathways. Proc Natl Acad Sci U S A (2006) 1.82
PD-L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction. Crit Care (2010) 1.73
PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. Mol Immunol (2007) 1.58
Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients. Crit Care (2011) 1.52
The anti-inflammatory response dominates after septic shock: association of low monocyte HLA-DR expression and high interleukin-10 concentration. Immunol Lett (2004) 1.37
Negative signaling contributes to T-cell anergy in trauma patients. Crit Care Med (2007) 1.22
Analytical requirements for measuring monocytic human lymphocyte antigen DR by flow cytometry: application to the monitoring of patients with septic shock. Clin Chem (2002) 1.20
Both percentage of gammadelta T lymphocytes and CD3 expression are reduced during septic shock. Crit Care Med (2005) 1.18
B and T lymphocyte attenuator tempers early infection immunity. J Immunol (2009) 1.18
Induction of global anergy rather than inhibitory Th2 lymphokines mediates posttrauma T cell immunodepression. Clin Immunol (2000) 1.17
Upregulation of the pro-apoptotic genes BID and FAS in septic shock patients. Crit Care (2010) 0.92
Nosocomial infection after septic shock among intensive care unit patients. Infect Control Hosp Epidemiol (2008) 0.91
Perioperative gene expression analysis for prediction of postoperative sepsis. Clin Chem (2010) 0.89
Editorial: PD-1, a new target for sepsis treatment: better late than never. J Leukoc Biol (2010) 0.87
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 13.52
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet (2006) 12.98
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol (2007) 9.29
A trial of intraoperative low-tidal-volume ventilation in abdominal surgery. N Engl J Med (2013) 6.91
MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J Exp Med (2007) 5.48
Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis (2013) 5.00
Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol (2013) 4.38
PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. Proc Natl Acad Sci U S A (2009) 4.23
Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol (2008) 4.10
Outcomes in severe sepsis and patients with septic shock: pathogen species and infection sites are not associated with mortality. Crit Care Med (2011) 3.43
Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol (2008) 3.34
Splenic stroma drives mature dendritic cells to differentiate into regulatory dendritic cells. Nat Immunol (2004) 3.25
Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony. Mol Med (2008) 2.93
Laryngeal injuries and intubating conditions with or without muscular relaxation: an equivalence study. Can J Anaesth (2008) 2.78
De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial. Intensive Care Med (2014) 2.77
Changes in choroidal thickness after panretinal photocoagulation in patients with type 2 diabetes. Retina (2015) 2.71
Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia. Crit Care Med (2005) 2.61
Protein kinase cδ deficiency causes mendelian systemic lupus erythematosus with B cell-defective apoptosis and hyperproliferation. Arthritis Rheum (2013) 2.60
Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med (2006) 2.56
Increased percentage of CD4+CD25+ regulatory T cells during septic shock is due to the decrease of CD4+CD25- lymphocytes. Crit Care Med (2004) 2.51
L-alanyl-L-glutamine dipeptide-supplemented total parenteral nutrition reduces infectious complications and glucose intolerance in critically ill patients: the French controlled, randomized, double-blind, multicenter study. Crit Care Med (2006) 2.51
Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol (2007) 2.51
Treatment of hypertension in patients 80 years and older: the lower the better? A meta-analysis of randomized controlled trials. J Hypertens (2010) 2.49
Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair. Cell Res (2010) 2.46
J-shaped relationship between blood pressure and mortality in hypertensive patients: new insights from a meta-analysis of individual-patient data. Ann Intern Med (2002) 2.45
Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia. Crit Care Med (2003) 2.40
Leukocyte apoptosis and its significance in sepsis and shock. J Leukoc Biol (2005) 2.38
First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J Clin Oncol (2012) 2.36
Increased circulating regulatory T cells (CD4(+)CD25 (+)CD127 (-)) contribute to lymphocyte anergy in septic shock patients. Intensive Care Med (2008) 2.34
Marked elevation of human circulating CD4+CD25+ regulatory T cells in sepsis-induced immunoparalysis. Crit Care Med (2003) 2.32
Low monocyte human leukocyte antigen-DR is independently associated with nosocomial infections after septic shock. Intensive Care Med (2010) 2.31
The genome and transcriptomes of the anti-tumor agent Clostridium novyi-NT. Nat Biotechnol (2006) 2.31
Outcome of acute mesenteric ischemia in the intensive care unit: a retrospective, multicenter study of 780 cases. Intensive Care Med (2015) 2.25
Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res (2005) 2.20
Short telomeres and prognosis of hypertension in a chinese population. Hypertension (2009) 2.18
Stable gene transfer and expression in cord blood-derived CD34+ hematopoietic stem and progenitor cells by a hyperactive Sleeping Beauty transposon system. Blood (2009) 2.15
Plasma microRNAs as novel biomarkers for endometriosis and endometriosis-associated ovarian cancer. Clin Cancer Res (2013) 2.15
Severe myoclonic epilepsy in infancy: a systematic review and a meta-analysis of individual patient data. Epilepsia (2007) 2.13
Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology (2011) 2.10
Messenger RNA expression of major histocompatibility complex class II genes in whole blood from septic shock patients. Crit Care Med (2005) 2.07
Circulating miR-210 as a Novel Hypoxia Marker in Pancreatic Cancer. Transl Oncol (2010) 2.03
Structure-based design of novel inhibitors of the MDM2-p53 interaction. J Med Chem (2012) 2.01
Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res (2009) 1.99
In vivo delivery of caspase-8 or Fas siRNA improves the survival of septic mice. Blood (2005) 1.99
TMEM16A induces MAPK and contributes directly to tumorigenesis and cancer progression. Cancer Res (2012) 1.98
Regulatory T cell populations in sepsis and trauma. J Leukoc Biol (2007) 1.96
Early identification of patients at risk for difficult intubation in the intensive care unit: development and validation of the MACOCHA score in a multicenter cohort study. Am J Respir Crit Care Med (2013) 1.90
The compensatory anti-inflammatory response syndrome (CARS) in critically ill patients. Clin Chest Med (2008) 1.86
Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLoS Med (2012) 1.85
Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia. Crit Care Med (2008) 1.75
Monitoring temporary immunodepression by flow cytometric measurement of monocytic HLA-DR expression: a multicenter standardized study. Clin Chem (2005) 1.74
miR-221 and miR-155 regulate human dendritic cell development, apoptosis, and IL-12 production through targeting of p27kip1, KPC1, and SOCS-1. Blood (2011) 1.73
The contribution of CD4+ CD25+ T-regulatory-cells to immune suppression in sepsis. Shock (2007) 1.71
Assessment of pro-vasopressin and pro-adrenomedullin as predictors of 28-day mortality in septic shock patients. Intensive Care Med (2009) 1.69
Pulmonary contusion causes impairment of macrophage and lymphocyte immune functions and increases mortality associated with a subsequent septic challenge. Crit Care Med (2005) 1.65
The role of tumor cell-derived connective tissue growth factor (CTGF/CCN2) in pancreatic tumor growth. Cancer Res (2009) 1.64
A bacterial protein enhances the release and efficacy of liposomal cancer drugs. Science (2006) 1.64
Reliability of mini-bronchoalveolar lavage for the measurement of epithelial lining fluid concentrations of tobramycin in critically ill patients. Intensive Care Med (2007) 1.64
High-volume haemofiltration with a new haemofiltration membrane having enhanced adsorption properties in septic pigs. Nephrol Dial Transplant (2008) 1.63
Decreased T-cell repertoire diversity in sepsis: a preliminary study. Crit Care Med (2013) 1.62
Silencing of Fas, but not caspase-8, in lung epithelial cells ameliorates pulmonary apoptosis, inflammation, and neutrophil influx after hemorrhagic shock and sepsis. Am J Pathol (2005) 1.60
Variable compliance with clinical practice guidelines identified in a 1-day audit at 66 French adult intensive care units. Crit Care Med (2012) 1.60
Assessment of plasmatic immunoglobulin G, A and M levels in septic shock patients. Int Immunopharmacol (2011) 1.60
GM130, a cis-Golgi protein, regulates meiotic spindle assembly and asymmetric division in mouse oocyte. Cell Cycle (2011) 1.60
Activated partial thromboplastin time waveform analysis: a new tool to detect infection? Crit Care Med (2006) 1.59
Clinical and therapeutic features of nonpostoperative nosocomial intra-abdominal infections. Ann Surg (2004) 1.57
Background infusion is not beneficial during labor patient-controlled analgesia with 0.1% ropivacaine plus 0.5 microg/ml sufentanil. Anesthesiology (2004) 1.55
Tumor necrosis factor-alpha-stimulated polymorphonuclear leukocytes suppress migration and bactericidal activity of polymorphonuclear leukocytes in a paracrine manner. Crit Care Med (2002) 1.52
Does a change in angiotensin II formation caused by antihypertensive drugs affect the risk of stroke? A meta-analysis of trials according to treatment with potentially different effects on angiotensin II. J Hypertens (2007) 1.51
Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab (2005) 1.51